Know Cancer

or
forgot password

Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)


N/A
18 Years
80 Years
Open (Enrolling)
Female
Breast Neoplasms, Arthralgia, Arthritis, Genetic Polymorphism

Thank you

Trial Information

Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)


Inclusion Criteria:



1. The patient must sign the informed consent.

2. The patient must sign the informed consent of genetic screening test.

3. The patient must be between 18 years old and 80 years old who can make a decision
independently.

4. The patient must be post-menopause status.

5. The patient should be the stage 1,2 or 3 of the breast cancer.

6. The test result of the estrogen receptor or progesterone receptor is positive, so the
patient should be taking the medication of AI (Aromatase Inhibitor).

Exclusion Criteria:

1. The patient is pre-menopause status.

2. The test result of serum FSH level is below 30mU/ml.

3. The test result of the hormone receptor(ER & PR) is negative or unknown.

4. Patient's breast cancer stage is 4 which has systemic metastatics.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Change of SNPs (PCR & sequencing), Estrogen, Inflammatory Cytokine level

Outcome Time Frame:

6, 12 months

Safety Issue:

No

Principal Investigator

Eun Sook Lee, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Korea University Anam Hospital

Authority:

Republic of Korea: Institutional Review Board

Study ID:

AN09021

NCT ID:

NCT00973505

Start Date:

March 2009

Completion Date:

September 2010

Related Keywords:

  • Breast Neoplasms
  • Arthralgia
  • Arthritis
  • Genetic Polymorphism
  • Breast neoplasms
  • Aromatase inhibitors
  • Genetic polymorphisms
  • Arthralgia
  • Arthritis
  • Arthralgia
  • Arthritis
  • Breast Neoplasms
  • Neoplasms

Name

Location